SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-21-125683
Filing Date
2021-10-13
Accepted
2021-10-13 08:34:56
Documents
14
Period of Report
2021-10-13
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2129746d1_8k.htm   iXBRL 8-K 27819
2 EXHIBIT 99.1 tm2129746d1_ex99-1.htm EX-99.1 10873
  Complete submission text file 0001104659-21-125683.txt   266180

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA nrxp-20211013.xsd EX-101.SCH 3617
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nrxp-20211013_def.xml EX-101.DEF 27305
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE nrxp-20211013_lab.xml EX-101.LAB 36882
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nrxp-20211013_pre.xml EX-101.PRE 25930
7 EXTRACTED XBRL INSTANCE DOCUMENT tm2129746d1_8k_htm.xml XML 5288
Mailing Address 1201 N. MARKET STREET SUITE 111 WILMINGTON DE 19801
Business Address 1201 N. MARKET STREET SUITE 111 WILMINGTON DE 19801 484-254-6134
NRX Pharmaceuticals, Inc. (Filer) CIK: 0001719406 (see all company filings)

IRS No.: 822844431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38302 | Film No.: 211320216
SIC: 2834 Pharmaceutical Preparations